Objective: Ketamine hydrochloride (KET), an agent used for general anesthesia, has local anesthetic effects and N-methyl-D-aspartate (NMDA) receptor antagonist action. Because recent studies emphasized the role of peripherally distributed NMDA receptors in processing the nociceptive information, we investigated whether peripheral application of the ointment containing KET is able to attenuate the symptoms of local neuropathic pain.
A llodynia and hyperalgesia, abnormal pain symptoms accompanying the complex regional pain syndrome type I (CRPS I), are major findings of posttraumatic neuropathic pain. They are usually managed by sympathetic block or medications, such as nonsteroidal anti-inflammatory drugs, anticonvulsants, and antidepressants. 1 In some cases, however, this approach is not effective enough, and other treatments are needed. 2 Among the ways to control allodynia and hyperalgesia in CRPS I patients is to use drugs that target glutamate receptors. Numerous studies showed the role of these receptors in processing of pain and report that antagonists of glutamate receptors are effective. [3] [4] [5] The N-methyl-D-aspartate (NMDA) receptor, 1 of 3 identified ionotropic glutamate receptor subtypes, is widely distributed throughout the central nervous system. 6 In the spinal cord, NMDA receptors are involved in pain transmission and are involved in allodynia and hyperalgesia. In animal models, NMDA receptors were found to be responsible for the formation of experimental neuropathic pain. 7, 8 It is also reported that both intravenous and oral administration of NMDA receptor antagonists attenuate neuropathic pain in humans. 9, 10 In addition to their central locations, recent morphologic and behavioral studies also found glutamate receptors, including the NMDA receptor, on peripheral axons and terminals. 11 Animal studies showed their role in nociceptive signaling. [12] [13] [14] [15] It was also reported that experimentally induced inflammation in the periphery increases the number of NMDA receptors on peripheral nerve fibers. 16 In humans, intradermal and intravenous regional ad-ministration of ketamine hydrochloride (KET) produced a local anesthetic effect and attenuated burninduced primary and secondary hyperalgesia. [17] [18] [19] Taking all these findings into account, we examined whether application of KET ointment is of therapeutic value for patients with allodynia or hyperalgesia.
Case Reports

Patient 1
A 36-year-old man injured his right hand by carelessly using an iron-compressing machine. Later he developed a spontaneous, unendurable pain of the injured hand. The pain was accompanied by severe swelling. Although radiologic examination did not reveal any abnormalities, hypesthesia and dysesthesia of thumb, index, and long fingers were found during clinical examination. Five days after the injury, a traumatic nerve lesion was suspected, and a surgical carpal tunnel release was performed. One week after surgery, the hypesthesia of the fingers improved, but the allodynia, spontaneous burning, and motion pain remained unchanged. Eventually, the patient developed increased sweating of the affected hand and was referred to our clinic for treatment.
We performed a diagnostic examination including phentolamine and tourniquet tests, thermogram and bone scintigram, and suggested CRPS I as a diagnosis. Oral medications, including alphablockers, NSAIDs, and intravenous regional sympathetic blocks, were initiated as a treatment. As a result, the pain score improved (visual analog scale [VAS]: 8 3 5.6). The increased sweating also subsided. However, the remaining allodynia prevented the patient from returning to work. To cope with allodynia, we applied hydrophilic ointment (100 g) containing 0.25% KET. Other components of the ointment were white petrolatum (25 g), cetanol (20 g), propylene glycol (12 g), polyoxyethylene 60 hydrogenated castor oil (4 g), glycerol monostearate (1 g), methyl paraoxybenzoate (0.1 g), propyl paraoxybenzoate (0.1 g), and distilled water. It was applied to the affected hand 3 times a day. No apparent changes of the symptoms were observed immediately after application. Three days later, however, the allodynia decreased. We then increased the concentration of KET to 0.5% and observed a further decrease in the allodynia and hyperalgesia as rapidly as 20 to 30 minutes after starting the application. We continued applications using 0.5% KET and applying the ointment 3 times a day. Two days later, the swelling, increased sweating, and the color of the hand improved. The VAS improved to 2.1 2 weeks later; improvement of the range of motion of the wrist and fingers was also noticed. As a control, we applied the same ointment lacking KET for 1 week. No improvement was reported by the patient during that period of time.
To investigate whether topical application of KET is able to change mechanical threshold in CRPS I, we determined the patient's touch and pain thresholds using von Frey filaments before and after KET application. The touch threshold was defined as the pressure (measured in millinewtons) necessary to evoke sensation of touch. The pain threshold was measured as the pressure (mN) required to evoke noxious sensation. We observed that hyperalgesia and allodynia of the affected hand improved 20 minutes after topical application of 0.5% KET. Thereafter, touch threshold increased from 1.47 mN to 4.31 mN, and pain threshold increased from 29.4 mN to 49.0 mN, respectively. These results showed that peripherally administered 0.5% KET attenuates not only nociceptive but also nonnoxious touch and pressure signals.
Patient 2
A 48-year-old man suffered whiplash injury in a traffic accident in 1994. Eventually, he developed swelling of the right hand and complained of nausea, vomiting, and headache. Magnetic resonance imaging analysis of cervical spine showed only a mild disc bulging. Appropriate medications and physical therapy were prescribed. Treatment continued for 2 years. Despite the treatment, the patient developed spontaneous burning pain and increased and nearly continuous sweating of the entire upper right limb. At this time, radiologic examination suggested CRPS I, and the patient was treated with stellate ganglion and continuous epidural blocks and transcutaneous electrical stimulation. The treatment lasted for an additional 2 years. As a result, swelling of the affected arm has partially improved, although pain has not subdued. The patient was then referred to our hospital where he received alpha-blockers and amitriptyline hydrochloride. An intravenous regional sympathetic block was performed. This treatment normalized sweating and improved symptoms of spontaneous burning pain. Paresthesia and allodynia, however, remained unchanged. To treat remaining symptoms, 0.8% KET ointment was applied 3 times a day. One week later, the color of affected arm has significantly improved. The allodynia and paresthesia were attenuated as well (VAS: 8.5 3 4.8).
Other Cases
Having observed improvements of CRPS symptoms after using KET ointment on 2 patients de-scribed previously, we used it on another 3 patients with CRPS I and on 2 patients with CRPS II (Table  1) . Relief of pain, at least partial relief, was reported by 2 CRPS I patients 1 to 2 weeks after KET administration began. No pain relief was achieved in CRPS II patients.
Discussion
Our findings suggest that topical application of an ointment containing KET within the range of concentration from 0.25% to 1.5% is an additional approach to attenuate allodynia in CRPS I patients. Although the specific mechanism of KET action in our study remains unclear, we suggest that local anesthetic effects of KET are relevant; it was reported that intracutaneous injections of 0.1% KET cause hypesthesia to noxious and nonnoxious mechanical stimulations. 17 Interestingly, the analgesic effects of KET ointment were noticed at the concentration of KET as low as 0.25% (ketamine hydrochloride used in this study contained equal amounts of dextro [R] and levo [L] isomers). It is likely that if it were injected in the affected area directly, similar analgesic effects might have allowed an even lower concentration to be effective. This is important because the lowest concentration of KET reported to date that produces local analgesic effects is 0.3%. 18 Therefore, some other mechanism(s) may be at work as well.
Another possible explanation of the efficiency of KET ointment is its action on NMDA receptors. Animal studies identified several glutamate receptors, such as NMDA, amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate with action on unmyelinated, myelinated, and postganglionic sympathetic axons. It was suggested that these peripherally distributed receptors play a role in the transmission of sensory signals to the central nervous system. 20, 21 These findings are supported by the clinical report that intraplantar injections of glutamate or glutamate receptor agonists result in nociceptive behaviors similar to mechanical hyperalgesia and allodynia. These nociceptive behaviors can be attenuated by peripheral administration of NMDA and non-NMDA receptor antagonists. 15 In addition, peripheral administration of MK-801, a noncompetitive antagonist of NMDA receptors, produces local anesthetic-like effects on the periphery. 22 In another human study, very low concentrations of peripherally administrated KET inhibited burn and injury-induced secondary hyperalgesia, suggesting that peripheral NMDA receptors are likely involved in peripheral sensory signaling. 20 Importantly, we observed a difference in the effectiveness of KET in CRPS I and CRPS II patients. In CRPS I patients, mechanisms related to the development of hyperalgesia and allodynia likely involve dysfunctions of central, peripheral, and/or autonomic nervous systems. In such patients, neurotransmitters secreted from peripheral nerve endings are probably an important cause of swelling and pain. Thus, control of neurosecretion and inhibition of abnormal axonal reflexes by local anesthetic effects of KET should prove to be important. Three of 5 CRPS I patients in our study showed a good response to the KET ointment. Another one showed a partial response. Only one CRPS I patient showed no apparent improvement, but the duration of disease in his case was significantly longer. Therefore, we suggest that KET ointment may be used for treatment of the earlier stage of disease but may not be effective in the later stages. When speculating on the reason KET was not effective for CRPS II patients, we hypothesize that the extent of nerve involvement in the disease may be the explanation. Although CRPS I and CRPS II patients share common clinical symptoms of posttraumatic pain, clear lesion of nerves in the case of CRPS I patients is usually not found. In contrast, CRPS II (causalgia) patients have a history of definable nerve lesion. 23 Thus, in our limited observations, it appears the clinical applicability of KET ointment is in cases when the nerves are not directly involved.
Further studies should clarify this observation. To conclude, this study suggests that topical applications of KET may be an additional approach to block peripheral pain transmission in patients with acute-early stage CRPS I.
